Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2022-05-19 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于召开2021年度暨2022年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of an upcoming earnings explanation meeting (业绩说明会) for the 2021 annual and 2022 first quarter results. It provides the meeting time, location, participation method, and contact information. It does not contain actual financial data or detailed financial statements but rather informs investors about the event where such information will be discussed. The document length is short (1521 characters) and it is clearly an announcement of a meeting rather than the meeting transcript or the financial report itself. Therefore, it fits best into the category of a Call Transcript announcement or Investor Presentation announcement. However, since it is specifically about an earnings explanation meeting (业绩说明会), which is a form of investor presentation focused on financial results, the most appropriate classification is Investor Presentation (IP).
2022-05-19 Chinese
亚宝药业集团股份有限公司2021年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled "亚宝药业集团股份有限公司 2021 年年度股东大会会议资料" which translates to "Yabao Pharmaceutical Group Co., Ltd. 2021 Annual General Meeting (AGM) Meeting Materials." It contains detailed agenda items for the 2021 AGM, including reports such as the 2021 Annual Report, Board of Directors Work Report, Supervisory Board Work Report, Independent Directors' Report, Financial Statements, Profit Distribution Plan, and other proposals to be discussed and voted on at the AGM. The document also includes meeting procedures, voting instructions, and detailed reports that are typically presented at an AGM. The length is substantial (15,000 characters), and the content is the actual meeting materials, not just an announcement or a brief summary. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting.
2022-05-10 Chinese
亚宝药业集团股份有限公司第八届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 亚宝药业集团股份有限公司 regarding multiple items including the 2021 Annual Report, Supervisory Board work report, financial statements, profit distribution plan, internal control evaluation report, and the 2022 Q1 report. It also mentions approval of amendments to the company charter and supervisory board remuneration. The document is a formal announcement of meeting resolutions and approvals, not the full annual report or financial statements themselves. The length is short (1720 characters) and it summarizes approvals rather than providing detailed financial data. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal regulatory announcement of supervisory board resolutions and approvals related to annual and quarterly reports, but does not contain the full reports themselves.
2022-04-27 Chinese
亚宝药业集团股份有限公司董事会审计委员会2021年度履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board of Directors Audit Committee 2021 Annual Performance Report" of 亚宝药业集团股份有限公司. It details the audit committee's activities, meetings, supervision of external auditors, internal audit guidance, review of financial reports, internal control evaluation, and coordination with management and auditors for the year 2021. The content focuses on the audit committee's duties and their fulfillment during the year, rather than presenting the full audited financial statements or the full annual report. The document length is 3759 characters, which is relatively short and consistent with a committee report rather than a full annual report or audit report. It is not a certification letter or a brief announcement. Therefore, this document fits best as an Audit Report / Information (AR) since it is a standalone audit committee report on audit activities and internal controls for the year 2021, without being the full annual report (10-K) or just an announcement (RPA).
2022-04-27 Chinese
亚宝药业集团股份有限公司关于召开2021年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2021 Annual General Meeting (AGM) of 亚宝药业集团股份有限公司, including details about the meeting date, voting methods, agenda items, and proxy forms. It does not contain the actual annual report or financial statements but rather informs shareholders about the meeting and the items to be voted on, including the 2021 annual report and financial results. The document length is 3250 characters, which is relatively short and consistent with an announcement or notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself.
2022-04-27 Chinese
亚宝药业集团股份有限公司2021年年度报告
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It contains detailed sections typical of an annual report such as company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document includes audited financial figures, auditor's opinion, profit distribution plans, and comprehensive management discussion and analysis. The length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2021
2022-04-27 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.